Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty

Horm Res Paediatr. 2010;73(5):386-9. doi: 10.1159/000308172. Epub 2010 Apr 14.

Abstract

Background: The flare-up effect of GnRH analogues may cause transient uterine bleeding in girls affected with idiopathic central precocious puberty (ICPP).

Aims: To assess the incidence of endometrial bleeding and verify whether pretreatment with cyproterone acetate could counteract it.

Methods: Fifty-four girls affected by ICPP were divided into 2 groups. The first group (30 girls) was treated with triptorelin (3.75 mg, i.m. injection) every 28 days. The second group (24 girls) was treated with cyproterone acetate and triptorelin: cyproterone acetate (50 mg/m(2)) was administered every day for 8 weeks, and triptorelin (3.75 mg) was commenced 4 weeks after starting the cyproterone, then the intramuscular injection of triptorelin was repeated every 28 days.

Results: Eight of 54 girls (15%) had mild withdrawal bleeding. There were no differences in incidence between groups 1 and 2. Girls with pubertal uterus at pelvic ultrasound had a higher incidence of uterine bleeding than girls with infantile uterus (25 vs. 7%), but this difference was not significant.

Conclusion: Co-administration of cyproterone acetate and GnRH analogues does not significantly decrease the incidence of uterine bleeding.

MeSH terms

  • Child
  • Child, Preschool
  • Cyproterone Acetate / therapeutic use*
  • Female
  • Humans
  • Puberty, Precocious / drug therapy*
  • Retrospective Studies
  • Triptorelin Pamoate / administration & dosage
  • Triptorelin Pamoate / therapeutic use*
  • Ultrasonography
  • Uterine Hemorrhage / prevention & control*
  • Uterus / diagnostic imaging
  • Uterus / drug effects

Substances

  • Triptorelin Pamoate
  • Cyproterone Acetate